We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-6.91%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$488M
AUM Growth
-$65.2M
Cap. Flow
-$17.8M
Cap. Flow %
-3.65%
Top 10 Hldgs %
32.78%
Holding
126
New
4
Increased
19
Reduced
35
Closed
4

Top Buys

Rank Stock Value
1
DHR icon
Danaher
DHR
+$5.8M
2
INCY icon
Incyte
INCY
+$5.8M
3
BCR
CR Bard Inc.
BCR
+$5.67M
4
AKRX
Akorn Inc
AKRX
+$4.79M
5
EW icon
Edwards Lifesciences
EW
+$3.89M

Top Sells

Rank Stock Value
1
CAH icon
Cardinal Health
CAH
+$6.82M
2
ILMN icon
Illumina
ILMN
+$5.64M
3
AMSG
Amsurg Corp
AMSG
+$4.79M
4
SYK icon
Stryker
SYK
+$2.92M
5
CI icon
Cigna
CI
+$2.88M

Sector Composition

Rank Sector Weight
1 Healthcare 91.87%
2 Financials 0.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HCSG icon
76
Healthcare Services Group
HCSG
$1.74B
$1.49M 0.31%
38,100
– –
CAH icon
77
Cardinal Health
CAH
$53.5B
$1.44M 0.29%
20,000
-94,280
-82% -$6.82M
BMY icon
78
Bristol-Myers Squibb
BMY
$124B
$1.34M 0.28%
23,000
– –
ACAD icon
79
Acadia Pharmaceuticals
ACAD
$4.38B
$1.3M 0.27%
45,000
– –
UTHR icon
80
United Therapeutics
UTHR
$22.7B
$1.12M 0.23%
7,800
+1,500
+24% +$192K
INO icon
81
Inovio Pharmaceuticals
INO
$92.1M
$1.08M 0.22%
12,917
– –
IBB icon
82
iShares Biotechnology ETF
IBB
$9.39B
$1.06M 0.22%
12,000
-28,500
-70% -$2.59M
INSY
83
DELISTED
Insys Therapeutics, Inc.
INSY
$1.06M 0.22%
115,000
– –
TFX icon
84
Teleflex
TFX
$5.96B
$1.05M 0.21%
6,500
– –
LH icon
85
Labcorp
LH
$23.2B
$1.03M 0.21%
9,312
– –
ACHN
86
DELISTED
Achillion Pharmaceuticals
ACHN
$991K 0.2%
240,000
– –
ABBV icon
87
AbbVie
ABBV
$450B
$939K 0.19%
15,000
– –
ICPT
88
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$924K 0.19%
8,500
-5,000
-37% -$596K
ALNY icon
89
Alnylam Pharmaceuticals
ALNY
$35.7B
$899K 0.18%
24,000
– –
EXEL icon
90
Exelixis
EXEL
$14.1B
$895K 0.18%
60,000
– –
MOH icon
91
Molina Healthcare
MOH
$11.7B
$895K 0.18%
16,500
– –
CLVS
92
DELISTED
Clovis Oncology, Inc.
CLVS
$888K 0.18%
20,000
-23,000
-53% -$810K
EVHC
93
DELISTED
Envision Healthcare Holdings Inc
EVHC
$824K 0.17%
13,026
– –
BIB icon
94
ProShares Ultra NASDAQ Biotechnology
BIB
$84.1M
$818K 0.17%
20,500
-25,000
-55% -$1.07M
PTLA
95
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$808K 0.17%
36,000
– –
LABU icon
96
Direxion Daily S&P Biotech Bull 3X ETF
LABU
$617M
$788K 0.16%
1,259
– –
CVS icon
97
CVS Health
CVS
$137B
$765K 0.16%
9,700
– –
JUNO
98
DELISTED
Juno Therapeutics, Inc.
JUNO
$697K 0.14%
37,000
– –
GKOS icon
99
Glaukos
GKOS
$9.21B
$686K 0.14%
+20,000
New +$685K
ALDR
100
DELISTED
Alder Biopharmaceuticals
ALDR
$686K 0.14%
33,000
– –
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2016 Portfolio in Review

As of Q4 2016, Bellevue Group held 126 positions worth $488M, down 12% from $553M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Bellevue Group withdrew a net $17.8M in Q4 2016, closing 4 positions and reducing 35 holdings. Its most notable exit was Amsurg Corp, an estimated $4.79M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 92% a quarter earlier, followed by Financials.

Against the trend, Bellevue Group opened a new position in Danaher worth $5.76M.

  • Bellevue Group's largest Q4 2016 buy was Danaher: 83,472 shares worth $5.76M.
  • Bellevue Group added most to Incyte in Q4 2016, an estimated $5.8M increase.
  • Bellevue Group's biggest Q4 2016 reduction was Cardinal Health, cutting an estimated $6.82M.
  • Bellevue Group fully exited Amsurg Corp in Q4 2016, selling an estimated $4.79M.
  • Bellevue Group's ten largest holdings make up 33% of its $488M portfolio in Q4 2016.
  • Bellevue Group opened 4 new positions and closed 4 in Q4 2016.
  • Bellevue Group's portfolio value fell 12% quarter-over-quarter to $488M.

Based on Bellevue Group's 13F filing for Q4 2016, filed 10 Feb 2017.